Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.
Andrew Spencer, MD, MBBS, FRACP, FRCPA
Advertisement
Articles by Andrew Spencer, MD, MBBS, FRACP, FRCPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5